Suppr超能文献

双折射弱视筛查仪与单纯小角度斜视的比较性美国小儿眼科与斜视学会验证

Comparative AAPOS Validation of the Birefringent Amblyopia Screener with Isolated Small-Angle Strabismus.

作者信息

Arnold Robert W

机构信息

Alaska Blind Child Discovery, Alaska Children's Eye and Strabismus, Anchorage, AK, USA.

出版信息

Clin Ophthalmol. 2020 Jan 31;14:325-329. doi: 10.2147/OPTH.S242335. eCollection 2020.

Abstract

BACKGROUND

The Rebion blinq binocular birefringent ocular alignment screener was recently commercially released, but it did not yet have validation by American Association for Pediatric Ophthalmology and Strabismus (AAPOS) uniform guidelines.

METHODS

Children and adults from a high-risk eye practice had screening by blinq with validation by AAPOS 2003 guidelines. Then, the blinq was compared to the Adaptica 2WIN with CR corneal reflex strabismus estimation by AAPOS 2003 guidelines plus additional efforts to identify patients with diminished binocularity.

RESULTS

Blinq in 100 patients compared to 2003 AAPOS amblyopia risk factors (ARF) had sensitivity 67%, specificity 75% and PPV of 82%. Both blinq and 2WIN were completed by 87 patients median age 6.5 years. Sensitivity, specificity and positive predictive value (PPV) for blinq were 75%, 68% and 81% whereas 2WIN had 91%, 68% and 84%. The blinq referred two young patients with isolated, small-angle strabismic amblyopia that 2WIN refractive function passed.

CONCLUSION

Despite its non-refractive design to identify binocular foveation, blinq performed well with refractive and strabismic uniform risk factors and a PPV greater than 80%.

CLINICAL TRIALS REGISTRY

NCT04195711.

摘要

背景

Rebion blinq双目双折射眼位筛查仪最近已投入商业使用,但尚未通过美国小儿眼科与斜视协会(AAPOS)的统一指南验证。

方法

来自高危眼科诊所的儿童和成人接受了blinq筛查,并根据AAPOS 2003指南进行验证。然后,将blinq与Adaptica 2WIN进行比较,后者通过AAPOS 2003指南的CR角膜反射斜视估计,此外还采取了额外措施来识别双眼视功能减退的患者。

结果

100例患者使用blinq,与2003年AAPOS弱视危险因素(ARF)相比,敏感性为67%,特异性为75%,阳性预测值为82%。87例中位年龄6.5岁的患者完成了blinq和2WIN检查。blinq的敏感性、特异性和阳性预测值(PPV)分别为75%、68%和 81%,而2WIN的相应值分别为91%、68%和84%。blinq转诊了两名患有孤立性小角度斜视性弱视的年轻患者,而2WIN的屈光功能检查通过。

结论

尽管blinq采用非屈光设计来识别双眼中心凹注视,但在屈光和斜视统一危险因素方面表现良好,阳性预测值大于80%。

临床试验注册

NCT04195711。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b503/6999781/8283ff45864e/OPTH-14-325-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验